KPIs & Operating Metrics(New)

Balance Sheet

Accounts Payables Assets Capital Leases Cash & Current Investments Cash & Equivalents Common Equity Current Assets Current Deferred Revenue Current Leases Current Taxes Goodwill Goodwill & Intangibles Intangibles Inventory Liabilities and Shareholders Equity Liabilities from Discontinued Operations Liabilities from Discontinued Operations Long-Term Deferred Tax Long-Term Investments Minority Interest Non-Current Assets Non-Current Debt Non-Current Deferred Tax Liability Non-Current Deferred Tax Liability Notes Payables Other Accumulated Expenses Other Non-Current Assets Other Non-Current Liabilities Payables Pension Property, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables Receivables - Net Receivables - Other Retained Earnings Shareholder's Equity Shares Outstanding Short term Debt Short-term Investments Total Current Liabilities Total Debt Total Liabilities Total Non-Current Liabilities

Cash Flow Statement

Daily Values

Growth Metrics

Gsk (GSK) Non-Current Deffered Revenue (2017 - 2018)

Gsk has reported Non-Current Deffered Revenue over the past 2 years, most recently at $24.4 million for Q4 2018.

For Q4 2018, Non-Current Deffered Revenue fell 16.3% year-over-year to $24.4 million; the TTM value through Dec 2018 reached $24.4 million, down 16.3%, while the annual FY2018 figure was $25.4 million, 13.12% down from the prior year.
Non-Current Deffered Revenue for Q4 2018 was $24.4 million at Gsk, down from $29.2 million in the prior quarter.
Over five years, Non-Current Deffered Revenue peaked at $29.2 million in Q4 2017 and troughed at $24.4 million in Q4 2018.